← Product Code [MOL](/submissions/OB/subpart-f%E2%80%94obstetrical-and-gynecological-therapeutic-devices/MOL) · K971590 # TACTYLON CONDOM (K971590) _Sensicon Corp. · MOL · Oct 7, 1997 · Obstetrics/Gynecology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OB/subpart-f%E2%80%94obstetrical-and-gynecological-therapeutic-devices/MOL/K971590 ## Device Facts - **Applicant:** Sensicon Corp. - **Product Code:** [MOL](/submissions/OB/subpart-f%E2%80%94obstetrical-and-gynecological-therapeutic-devices/MOL.md) - **Decision Date:** Oct 7, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 884.5300 - **Device Class:** Class 2 - **Review Panel:** Obstetrics/Gynecology ## Indications for Use For Latex Sensitive Condom Users: This is a TACTYLON® condom. This is not a latex condom. You may use this TACTYLON ® condom if you or your partner are allergic to latex. You should know: . The risks of pregnancy and sexually transmitted diseases (STDs), including AIDS (HIV infection), are not known for this condom. A study is being done. . There are laboratory tests on this TACTYLON® material. These tests show that organisms even as small as sperm and viruses like HIV cannot pass through it. Latex condoms for men, if used correctly with every act of vaginal intercourse are highly effective at preventing pregnancy, as well as STDs, including AIDS (HIV infection). ## Device Story TACTYLON® condom; synthetic thermoplastic elastomer block copolymer (styrene-ethylene-butylene-styrene); alternative to Natural Rubber Latex (NRL) for latex-sensitive individuals. Device acts as physical barrier during vaginal intercourse. Material properties (strength, elasticity, tactility) equivalent to NRL; resistant to UV, ozone, oxygen, heat, and humidity due to lack of unsaturated bonds. Used by patients for contraception and STD prevention. Clinical trials confirm non-toxicity, non-irritation, and non-sensitization; breakage and slippage rates comparable to standard TACTYLON® condoms. Barrier efficacy validated via viral surrogate (φ X174) challenge. ## Clinical Evidence Clinical trials included a modified Draize test (n=200) showing no irritation or sensitization; use tests and skin prick tests in latex-sensitive individuals (n=20) showed no adverse reactions. Comparative clinical trial of lubricated TACTYLON® condoms evaluated breakage and slippage rates, finding performance similar to the predicate (K953582). ## Technological Characteristics Material: Styrene-ethylene-butylene-styrene thermoplastic elastomer block copolymer. Meets FDA Class VI requirements for nontoxicity. Non-reactive to UV, ozone, oxygen, heat, and humidity. Barrier performance validated via viral surrogate (φ X174) assay. ## Regulatory Identification A condom is a sheath which completely covers the penis with a closely fitting membrane. The condom is used for contraceptive and for prophylactic purposes (preventing transmission of sexually transmitted infections). The device may also be used to collect semen to aid in the diagnosis of infertility. ## Special Controls *Classification.* (1) Class II (special controls) for condoms made of materials other than natural rubber latex, including natural membrane (skin) or synthetic.(2) Class II (special controls) for natural rubber latex condoms. The guidance document entitled “Class II Special Controls Guidance Document: Labeling for Natural Rubber Latex Condoms Classified Under 21 CFR 884.5300” will serve as the special control. See § 884.1(e) for the availability of this guidance document. ## Predicate Devices - Standard TACTYLON® condom ([K953582](/device/K953582.md)) ## Reference Devices - Trojan-enz condom ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## LUBRICATED HIGH ELONGATION CONDOM 510(k) SUMMARY OCT - 7 1997 17 /15 96 1102 This summary of safety and effectiveness is being submitted in accordance with the requirements of the SMDA of 1990. - Substantial Equivalence: (A) | 1. | Submitted by: | Sensicon Corporation | |----|---------------|--------------------------------------| | | Address: | 2595 Commerce Way
Vista, CA 92083 | | | Telephone: | (760) 734-6690 | | | Contact: | Jeff Grant | - Natural Rubber Latex products present a risk of anaphylaxis for 2. individuals with Type I immediate hypersensitivity to Natural Rubber Latex (NRL) and can cause less dangerous, but uncomfortable, symptoms in individuals with Type IV delayed hypersensitivity. The synthetic TACTYLON® condom contains neither NRL protein allergens nor sensitizing chemicals. It therefore represents a suitable alternative for latex sensitive individuals. Furthermore, muscle exposure to NRL appears to be one of the primary routes of sensitization for Type I allergies.1 - The TACTYLON® condom is made from styrene-ethylene-butylene-3. styrene thermoplastic elastomer block copolymer but has physical properties (e.g., strength, elasticity, and tactility) and dimensions that are substantially equivalent to a NRL condom. - The safety and efficacy of TACTYLON® involves two major issues: the potential (B) allergenicity and toxicity of the material and the efficacy of the material's barrier. - The TACTYLON® block copolymer is a compound that meets the FDA 1. requirements for Class VI materials, the most stringent category for nontoxicity. The plastisizer used is a USP recognized by the FDA as safe for human consumption. Toxicity is therefore not a relevant safety issue as evidenced by the following studies of the non-lubricated Standard condom. Neither primary skin irritation nor vaginal mucosal irritation was found in a rabbit model. There was no evidence of irritation or toxicity in a 3-day, 7day, or 90-day surgical mucosal implantation study in a rabbit model. Furthermore, no delayed dermal sensitization occurred in a guinea pig model. No mutagenic changes were found in histidine dependent mutant strains of Salmonella typhimurium when exposed to either saline or DMSO 4 American Academy of Allergy & Immunology: Task force on allergic reactions to latex (committee report). J. Allergy Clin Immunol 1993; 92:16-18. {1}------------------------------------------------ extracts of TACTYLON®. In addition, there were no positive indicators resulting from a cytotoxicity test, by the USP elution method (MG 057), on samples which had been real-time aged for 14 months. Also, the lubricated condom was tested for cytotoxicity on unaged, as well as aged (oven conditioned), sample at 70°C for seven (7) days with no positive indicators. The lubricated condom was tested for systemic toxicity using Saline and Cottonseed Oil as well as for vaginal irritation in rabbits using saline extract. These tests both meet the USP requirements. The barrier properties of TACTYLON® are substantially equivalent to NRL as demonstrated by an in vitro challenge with a viral surrogate (φ X174) to simulate the HIV (AIDS) measured by an extremely sensitive assay. As with NRL products, however, petroleum-based lubricants should be avoided. Because the chemical structure of the copolymer has no unsaturated bond, TACTYLON® is resistant to conditions such as ultraviolet radiation, ozone, oxygen, heat and humidity, that can accelerate aging and adversely affect barrier properties. - Clinical trials conducted on the non-lubricated TACTYLON® material 2. indicated it is nontoxic, nonirritating, and nonsensitizing. In the modified Draize test conducted in 200 human subjects, TACTYLON® was nonirritating and nonsensitizing in all 200 subjects. When a group of 20 latex-sensitive individuals was subjected to use tests and skin prick tests, TACTYLON® caused no adverse reactions.2 - In a clinical trial of TACTYLON® lubricated condoms, the clinical 3. breakage and slippage rates as well as the subjective perceptions were studied. These trials showed that the clinical breakage of the High Elongation TACTYLON® condoms were similar to the Standard TACTYLON® condom cleared by 510(k) 953582.3 - 4. The results of both the nonclinical and the clinical studies suggest that TACTYLON® material is nonallergenic, nonirritating, and nontoxic when in contact with either the intact dermis or mucosal tissue for clinically relevant periods. Furthermore, the barrier was as impermeable to a viral surrogate as NRL in nonclinical studies and tolerated the stresses associated with use as well as NRL in a large clinical trial. The copolymer's chemistry confers a distinct advantage over NRL in terms of potential shelf-life. 2Lahti A, Camarasa JG, Ducombs G, et al: Patch tests with TACTYLON in patients with contact allergy to rubber. Contact Dermatitis 1992; 27:188. 3Trussell J, Warner DL, Hatcher RA: Condom performance during vaginal intercourse: comparison of Trojan-enz and TACTYLON condoms. Contraception 1992;45:11-19. {2}------------------------------------------------ Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of the department's name arranged in a circular fashion around a stylized emblem. The emblem features a symbol that resembles a stylized caduceus or a representation of human figures, with flowing lines suggesting movement or interaction. The overall design is simple and recognizable, representing the department's role in health and human services. OCT - 7 1997 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Jorge Haider Director Regulatory Affairs and Quality Assurance Sensicon Corporation 2595 Commerce Way · Vista, California 92083 Re: K971590 TACTYLON® Condom, Lubricated, High Elongation Dated: August 6, 1997 Received: August 8, 1997 Regulatory class: II 21 CFR §884.5300/Product code: 85 MOL Dear Mr. Haider: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitto diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for question and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours. W. Liao Yu Lillian Yin, Ph.D. Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ 510 (k) Number: Company Name: Device Name: ## K971590 Sensicon Corporation Male Condom Page 1 of 1 ## Indications For Use: For Latex Sensitive Condom Users: This is a TACTYLON® condom. This is not a latex condom. You may use this TACTYLON ® condom if you or your partner are allergic to latex. You should know: - . The risks of pregnancy and sexually transmitted diseases (STDs), including AIDS (HIV infection), are not known for this condom. A study is being done. - . There are laboratory tests on this TACTYLON® material. These tests show that organisms even as small as sperm and viruses like HIV cannot pass through it. Latex condoms for men, if used correctly with every act of vaginal intercourse are highly effective at preventing pregnancy, as well as STDs, including AIDS (HIV infection). (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Robert Rathbun (Division Sign-Off) (Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number_K971190 Prescription Use (Per 21 CFR 801.109) OR Over-The-Counter Use \$\checkmark\$ (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/OB/subpart-f%E2%80%94obstetrical-and-gynecological-therapeutic-devices/MOL/K971590](https://fda.innolitics.com/submissions/OB/subpart-f%E2%80%94obstetrical-and-gynecological-therapeutic-devices/MOL/K971590) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com